Inspira Set to Unveil HYLA™ Blood Sensor Results
Company Announcements

Inspira Set to Unveil HYLA™ Blood Sensor Results

Inspira Technologies Oxy BHN (IINN) has released an update.

Inspira Technologies Oxy BHN Ltd. has announced its intention to report clinical results for its innovative HYLA™ blood sensor in the fourth quarter of 2024, targeting the $2.5 billion Point of Care and ABG analyzer market. The HYLA™ sensor, which enables real-time monitoring of blood parameters during open-heart surgery, is a key part of Inspira’s long-term growth strategy and is expected to integrate with the FDA-cleared INSPIRA™ ART100 systems. Inspira is focusing on expanding its blood testing facilities and developing the HYLA™ sensor line to transform respiratory and life-support sectors, addressing a $59 billion annual market opportunity.

For further insights into IINN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskInspira Technologies Joins Glo-Med for U.S. Expansion
TheFlyInspira Technologies appoints Glo-Med as primary U.S. distributor
TipRanks Auto-Generated NewsdeskInspira Technologies Unveils Innovative Disposable Kit
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App